Cambridge Investment Research Advisors
ELDN icon

Cambridge Investment Research Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Buy
59,945
+11,743
+24% +$42.7K ﹤0.01% 3669
2026
Q1 		$148K Buy
+48,202
New +$114K ﹤0.01% 3740

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Cambridge Investment Research Advisors's ELDN Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Eledon Pharmaceuticals (ELDN) stake by 24% in Q2 2026, buying an estimated $42.7K and bringing the position to 59,945 shares worth $236K. The position accounts for ﹤0.01% of the portfolio, ranked #3669.

Cambridge Investment Research Advisors first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Cambridge Investment Research Advisors held 59,945 shares of Eledon Pharmaceuticals worth $236K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 11,743 Eledon Pharmaceuticals shares in Q2 2026, an estimated $42.7K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3669 holding.
  • Cambridge Investment Research Advisors first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.